Alto Neuroscience, INC 8-K filings

Alto Neuroscience, Inc. has successfully completed a registered direct offering of common stock, raising approximately $93.9 million to advance its clinical development programs.

Alto Neuroscience announced preliminary cash reserves of approximately $244.2 million as of June 30, 2026, and plans to accelerate clinical development of its ALTO-207 program.

Alto Neuroscience, Inc. has appointed biotechnology veteran Dr. Andrew Miller to its Board of Directors, effective May 27, 2026.

Alto Neuroscience, Inc. has filed an amendment to its 2024 Employee Stock Purchase Plan, approved by stockholders on May 12, 2026, to include pre-funded warrants in share reserve calculations.

Alto Neuroscience reported Q1 2026 results, highlighting the initiation of a Phase 2b trial for ALTO-207 in treatment-resistant depression and a $120 million PIPE financing.

Alto Neuroscience reported that its ALTO-101 drug candidate did not achieve statistical significance on its primary endpoint in a Phase 2 study for cognitive impairment associated with schizophrenia, shifting focus to ALTO-207.

Alto Neuroscience announced a $120 million private placement financing to advance its lead drug candidate, ALTO-207, for treatment-resistant depression.

Alto Neuroscience reports robust full-year 2025 financial results and significant clinical pipeline advancements, including a key acquisition and FDA Fast Track designation.

Alto Neuroscience reported strong Q3 2025 financial results, advanced its clinical pipeline with key FDA feedback and Fast Track designation, and bolstered its cash position with a $50 million private placement.

Alto Neuroscience announced a $50 million private placement to accelerate the development of its ALTO-207 program for Treatment Resistant Depression following a successful FDA meeting.

Alto Neuroscience reported Q2 2025 financial results, highlighted pipeline advancements including a new acquisition, and appointed Dr. Raymond Sanchez to its Board of Directors.

Alto Neuroscience, Inc. has approved a repricing of over 4.2 million underwater stock options for its employees and consultants, including key executives, to an exercise price of $2.35 per share, effective July 3, 2025, aiming to enhance retention and motivation.

Alto Neuroscience, Inc. announced positive pharmacodynamic results and the identification of a patient selection biomarker from its exploratory Phase 2 proof-of-concept trial of ALTO-203 for major depressive disorder.

Alto Neuroscience, Inc. announced the acquisition of a portfolio of dopamine agonist drug combinations from Chase Therapeutics Corporation, including ALTO-207 for treatment-resistant depression, extending its cash runway into 2028.

Alto Neuroscience announced its Q1 2025 financial results and highlighted progress in its clinical-stage pipeline, with key data readouts expected in the coming quarters.

Alto Neuroscience announced its full-year 2024 financial results, highlighting a strong cash position and advancements in its clinical-stage pipeline for neuropsychiatric disorders.

Alto Neuroscience reports a favorable outcome from the interim analysis of its ALTO-300 Phase 2b trial for major depressive disorder, leading to a continuation of the study with an increased target patient population.

Alto Neuroscience has entered into a sales agreement to potentially offer up to $75 million of its common stock through an at-the-market offering and disclosed a preliminary cash balance of approximately $168 million as of December 31, 2024.

Alto Neuroscience has amended its loan agreement, increasing the facility to $75 million and extending the maturity date, while also issuing new warrants.

Alto Neuroscience announced its third quarter 2024 financial results and provided updates on its clinical programs, highlighting upcoming data readouts for multiple trials in the first half of 2025.

Alto Neuroscience's Phase 2b trial of ALTO-100 for major depressive disorder did not meet its primary endpoint, though the drug showed a favorable safety profile.

Alto Neuroscience announced the completion of enrollment in a Phase 2b study for ALTO-100, initiation of multiple Phase 2 studies, and a strong cash position to fund operations into 2027.

Alto Neuroscience has entered into a convertible loan agreement with The Wellcome Trust Limited for up to $11.7 million to fund a Phase 2b clinical trial of ALTO-100 for bipolar depression.

Alto Neuroscience has appointed Michael Hanley as its new Chief Operating Officer, effective May 20, 2024.

Alto Neuroscience announced its first quarter 2024 financial results, highlighting progress in clinical trials and a strong cash position.

Alto Neuroscience announced its full year 2023 financial results, highlighting positive clinical trial results and a strong cash position following a successful IPO.

Alto Neuroscience has appointed Dr. Maha Radhakrishnan to its Board of Directors and Nominating and Corporate Governance Committee, effective March 8, 2024.

Alto Neuroscience has filed amended and restated certificate of incorporation and bylaws in connection with the closing of its initial public offering on February 6, 2024.